A Real World Study of the contact-cooled 1726 nm Laser System for the Treatment of Acne Vulgaris

David Goldberg, MD, Jeffrey Fromowitz, MD, FAAD, Margot Doucette, BS

AviClear®

Combination therapy is often used to treat moderate and severe acne, per current guidelines [1]

While the 1726nm is indicated for long term treatment of inflammatory acne vulgaris, the safety of repeated laser doses with concomitant medications is unknown

Patients received up to six doses of laser therapy while staying on their other acne treatment regimens and were followed for 1 year

PATIENT-REPORTED OUTCOMES*

65% **Concern Around Not Looking One's Best**
65.2% decrease in the percentage of patients who reported feeling concerned or worried about not looking their best because of the acne on their face *(74.0% at baseline and 8.8% at 52 weeks)*

49% **Decreased Embarrassment**
49.3% decrease in the percentage of patients who reported feeling embarrassed or self-conscious about the acne on their face *(64.0% at baseline and 14.7% at 52 weeks)*

41% **Reduced Feelings of Unattractiveness**
41.2% decrease in the percentage of patients who felt unattractive because of their acne *(50.0% at baseline and 8.8% at 52 weeks)*

38% **Reduced Impact on Social Life**
38.1% decrease in the percentage of patients who felt acne affected their social and leisure activities *(44.0% at baseline and 5.9% at 52 weeks)*

36% **Reduced Missing Out**
36.2% decrease in the percentage of patients who felt acne has caused them to miss out on important events and/or moments in their life *(48.0% at baseline vs. 11.8% at 52 weeks)*

SAFETY: Well-tolerated; no blistering, crusting, hypo- or hyperpigmentation


76% **SATISFACTION**: 76% of patients reported feeling "satisfied" or "very satisfied" at 12wkfu post tx 3

Study Data: Per Protocol Outcomes

Study population data includes patients who were followed until at least 12wkfu post tx 3


- 45 patients
- FST I-V
- Average Age: 22 years
- Age Range: 16-43 years
- Moderate Acne: 67%
- Severe Acne: 33%
- 21 subjects: 1-3 acne meds at baseline

Concomitant Medications throughout study



Primary Endpoint

Responder rate (% with ≥ 1-point reduction on IGA)



6 months (post 3 tx)



12 month (post 3, 5, or 6 tx)

Response at 52 weeks post 3, 5 or 6 tx

(n=34, per protocol)



24 year old female - 3 Tx total



Concomitant medication(s): None

34 year old female - 5 Tx total



Concomitant medication(s): Tretinoin, Clindamycin, and spironolactone

Conclusion

- Treatment of acne with multiple doses of laser plus concomitant medications is safe and effective over a 1 year follow up
- Treatment protocols can be customized to address multiple factors such as bacteria and inflammation, while reducing sebum production via the 1726nm laser
- Clinicians can further individualize treatments by offering additional laser sessions based on acne severity and response.

[1] Zaenglein AL, et al. J Am Acad Dermatol. 2016;74(5):945-973.e33. *Data are post-last treatment for patients who received 3, 5, or 6 treatments